导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 22.20% | 220/4773 |
| 近一周 | -2.55% | 2525/5462 |
| 近一月 | -4.76% | 2716/5421 |
| 近一季 | -3.28% | 1385/5209 |
| 近半年 | 21.33% | 118/4920 |
| 近一年 | 23.71% | 311/4366 |
| 近两年 | 133.28% | 312/2954 |
| 近三年 | 81.87% | 216/2253 |
| 成立以来 | 68.81% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.65% 3662/4961 |
46.51% 666/5312 |
- - |
- - |
| 2025 | 43.48% 666/4813 |
1.88% 1526/3635 |
3.60% 980/4076 |
42.82% 676/4524 |
-4.83% 3486/4813 |
| 2024 | 2.98% 1947/3463 |
-3.62% 1532/2808 |
-7.77% 2125/3014 |
13.87% 2084/3129 |
1.74% 1034/3463 |
| 2023 | 5.52% 187/2656 |
15.21% 218/2280 |
0.94% 260/2385 |
-8.61% 1711/2515 |
-0.72% 245/2655 |
| 2022 | -28.78% 1581/2207 |
-17.76% 1256/1919 |
-3.25% 1805/2016 |
-17.54% 1612/2113 |
8.55% 260/2208 |
| 2021 | 3.69% 604/1822 |
-6.99% 1051/1255 |
17.89% 178/1330 |
-10.59% 1227/1466 |
5.77% 269/1822 |
| 2020 | 34.44% 437/1250 |
4.29% 77/1028 |
24.23% 176/1067 |
2.19% 1009/1164 |
1.55% 1024/1184 |
| 2019 | - - |
- - |
- - |
- - |
8.49% 312/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 嘉实新兴科技100ETF VS. 长安沪深300非周期A(740101) |